No Data
Earnings Preview: NBIX to Report Financial Results Pre-market on October 30
Mizuho Securities Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $192
Express News | BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $114
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds?
Tonyco OP : Prolly 120 entry for long, else short now